HIPEC vs Conventional Chemotherapy: What Is the Difference, Which Treatment Is Better and When Is Each Used in India?

Both HIPEC and conventional chemotherapy use medicines to destroy cancer cells. The way those medicines reach the cancer is very different.

Conventional chemotherapy usually enters the bloodstream through a drip or tablets and can reach cancer cells in different organs. HIPEC is given during an operation: after the surgeon removes as much visible abdominal cancer as possible, heated chemotherapy is circulated directly inside the abdominal cavity.

HIPEC is not suitable for every cancer patient. It is mainly considered for selected cancers that have spread to the peritoneum. The coordinated pathway is HIPEC surgery in India. Named systemic pathways sit on chemotherapy in India.

GAF Healthcare planning for cytoreductive surgery with HIPEC is $18,000–$40,000, typically 10–21 nights. Neighbouring cytoreductive surgery is $10,000–$24,000 (7–14 nights). Named systemic chemotherapy planning is $1,500–$8,000+ (outpatient cycles · 3–6 months typical). Neighbouring PIPAC is $7,000–$16,000.

International patients comparing surgical oncologists listing CRS with HIPEC commonly start with Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. Medical oncology teams coordinate systemic therapy. Partner surgical-oncology hospitals in Delhi NCR, Mumbai and Bengaluru are a typical first filter.

Conventional chemotherapy uses medicines to kill cancer cells or slow their growth. Most regimens are given through a vein; some medicines are tablets. Because the drug travels in the bloodstream, doctors call it systemic chemotherapy.

Treatment usually follows cycles — medicine days followed by rest — so the body can recover. The number of cycles depends on cancer type, stage, response and fitness.

Medicines and schedules differ by cancer. See chemotherapy in India for the coordinated systemic pathway.

HIPEC stands for Hyperthermic Intraperitoneal Chemotherapy — heated chemotherapy given directly inside the abdomen during surgery, usually as part of cytoreductive surgery (CRS) with HIPEC.

During CRS, the surgeon removes visible deposits from the abdominal lining and, where needed, affected tissues or organs. Heated chemotherapy is then circulated so it contacts surfaces where microscopic cells may remain.

The solution is warmed to a controlled temperature, commonly around 40–42°C, depending on protocol. Heat may help drug action and tissue penetration. Heating alone does not make HIPEC automatically more effective than systemic chemotherapy.

Exact medicines, temperature and duration vary by cancer and centre. Read What is HIPEC surgery? and the flagship HIPEC surgery in India guide.

The treatments are different, but doctors may use them in the same plan. Catheter-based intraperitoneal chemotherapy and PIPAC are related but distinct pathways.

No. HIPEC is a local treatment focused on the abdominal cavity. Systemic chemotherapy can reach cancer throughout the body.

Do not assume HIPEC is always stronger or better than regular chemotherapy.

Yes, in selected multimodal plans. For example, a patient with colorectal cancer and peritoneal metastases may receive systemic chemotherapy first; if disease responds and is resectable, CRS (with or without HIPEC, depending on evidence and protocol) may be assessed. Further systemic therapy may follow.

This approach is not suitable for everyone. Decisions depend on tumour behaviour, disease location, resectability and fitness. For colorectal peritoneal disease, also see colon cancer treatment in India and stage 4 colon cancer treatment.

CRS-HIPEC may be considered for selected peritoneal surface malignancies:

Usually linked to an appendiceal mucinous tumour. For operable disease, CRS-HIPEC is an established specialist approach — see pseudomyxoma peritonei treatment.

Selected patients with peritoneal spread may be considered for CRS-HIPEC depending on type, grade and extent — see appendix cancer treatment and HIPEC.

HIPEC may be considered for selected women with advanced epithelial ovarian cancer during interval surgery after chemotherapy. Stage, response, kidney function and fitness matter — see ovarian cancer treatment in India.

Some patients with disease limited to the peritoneum may be considered for cytoreductive surgery. The additional role of HIPEC is more controversial. ASCO does not recommend adding oxaliplatin-based HIPEC to CRS for colorectal peritoneal metastases. CRS plus systemic chemotherapy may still be considered when complete cytoreduction is feasible and there is no extra-peritoneal disease.

Systemic treatment is generally central. CRS-HIPEC is not routine for all patients with peritoneal spread and may be discussed only in carefully selected settings — see HIPEC surgery for stomach cancer.

For selected patients with resectable disease, CRS-HIPEC may be considered at an experienced centre.

Important: Appearing on this list does not mean every patient with that cancer is eligible for HIPEC.

A patient with colorectal cancer involving liver, lungs and peritoneum may need a systemic plan rather than an abdomen-only operation. See peritoneal metastases treatment and peritoneal carcinomatosis.

HIPEC may be considered when cancer is mainly on peritoneal surfaces and removing visible deposits appears beneficial. Teams assess cancer type, extent, resectability, PCI score, fitness, extra-abdominal disease and prior treatment response.

There is no single PCI cut-off that applies to every cancer. Distribution — especially small-bowel involvement — matters. See Peritoneal Cancer Index (PCI).

There is no single answer. Effectiveness depends on cancer type, stage, location and patient condition.

The PRODIGE 7 trial did not show an overall survival benefit from adding the oxaliplatin-based HIPEC regimen studied to cytoreductive surgery. Based on this evidence, ASCO recommends against adding oxaliplatin-based HIPEC to CRS for colorectal peritoneal metastases. The benefit of removing visible disease and the additional benefit of HIPEC are separate questions.

OVHIPEC-1 supports considering HIPEC during interval cytoreductive surgery for selected women with stage III epithelial ovarian cancer after neoadjuvant chemotherapy who meet fitness requirements. This should not be applied to every ovarian cancer patient or stage.

For suitable operable PMP, CRS-HIPEC remains an established specialist approach. Extent, grade, completeness of cytoreduction and health still decide outcomes.

Side effects depend on medicines, dose, cycles and general health. Fever with low counts, uncontrolled vomiting, chest pain or severe bleeding needs urgent local care.

CRS-HIPEC combines major surgery with chemotherapy exposure. Risks may include infection, bleeding, clots, bowel leakage, temporary or prolonged bowel problems, kidney injury with certain drugs, low blood counts, fluid and electrolyte imbalance, slow wound healing, ICU care and longer stay.

Ask about expected benefits, major risks, stoma possibility, hospital stay and the centre's experience before agreeing to surgery. Sudden severe pain, fever, collapse or inability to pass stool or gas belongs in a local emergency department.

Many regimens are outpatient. Patients may feel tired or nauseated for a few days. Blood tests guide the next cycle. Treatment may continue for months.

Recovery is usually longer: ICU or high-dependency monitoring, pain control, fluids, gradual nutrition, kidney and blood-count checks, wound care and staged return to walking. GAF planning for CRS with HIPEC typically quotes 10–21 nights. Full recovery may take several weeks or longer.

HIPEC should not be described as a guaranteed cure. Selected patients may achieve long-term control; others experience recurrence. Goals may be cure, long-term control, slowing disease or symptom relief — the team should state which applies.

Before (neoadjuvant): to treat whole-body disease, reduce burden, assess response and identify progressing disease. Example: interval cytoreduction with possible HIPEC after chemotherapy in selected ovarian cancer.

After (adjuvant): based on final pathology, residual disease risk, prior drugs and recovery. Some patients are observed without immediate further chemotherapy.

A multidisciplinary team — medical oncologist, surgical oncologist experienced in peritoneal disease, radiologist, pathologist, anaesthesia/critical care and nutrition — reviews diagnosis, scans, pathology, prior therapy and fitness.

PCI helps describe burden (0–39) but is not a universal eligibility rule. See the PCI guide.

India offers specialist evaluation including CRS-HIPEC assessment. Do not travel assuming HIPEC will definitely be recommended. Start with record review.

Ask whether diagnosis is pathology-confirmed, whether disease is abdomen-limited, whether CRS-HIPEC or systemic therapy is being considered, treatment goals, resectability, HIPEC drug if planned, major risks, stay length and follow-up after return home.

Costs differ because the pathways differ. CRS-HIPEC includes major surgery, specialist teams, theatre, anaesthesia, ICU, admission and perfusion drugs. Systemic chemotherapy costs depend on medicines, cycles, day-care charges, labs, scans and supportive drugs.

City CRS-HIPEC sheets: Delhi NCR, Mumbai, Bengaluru, Chennai, Hyderabad. The national CRS-HIPEC band remains $18,000–$40,000.

Comparing one HIPEC operation with a single chemotherapy cycle is not meaningful. Request an itemised estimate after medical review. The cheapest quote should not outweigh surgical experience and complication management.

GAF Healthcare helps international patients organise records, arrange specialist consultations, share DICOM and pathology, request treatment-plan discussions and estimates, coordinate appointments, and assist with travel and follow-up communication.

GAF does not diagnose cancer or independently decide HIPEC eligibility. Those decisions belong to the treating team.

There is no universal answer. Multi-organ disease often needs systemic chemotherapy. Selected peritoneal disease may be assessed for cytoreductive surgery with or without HIPEC. Some patients receive both at different stages; others never need HIPEC.

Do not stop, delay or replace prescribed chemotherapy with HIPEC without discussing the decision with the treating oncologist.

Conventional chemotherapy usually travels through the bloodstream to treat cancer throughout the body. HIPEC delivers heated chemotherapy directly into the abdominal cavity during surgery, mainly to target cancer cells on the abdominal lining.

Not in every situation. HIPEC may help selected patients with peritoneal disease. Systemic chemotherapy remains essential for cancer throughout the body. The right choice depends on cancer type and spread.

No. HIPEC does not automatically replace conventional chemotherapy. Some patients receive both; others need only one approach or a different plan.

Yes. Some patients receive systemic chemotherapy before or after CRS-HIPEC. Timing depends on tumour type, response and fitness.

Yes. HIPEC is chemotherapy delivered differently: heated and circulated inside the abdomen during an operation, usually after cytoreductive surgery.

The solution is warmed to a controlled temperature (often around 40–42°C) because heat may aid drug action and tissue penetration. Benefit depends on cancer type and protocol.

No. HIPEC targets surfaces inside the abdominal cavity. Disease outside the abdomen usually needs systemic treatment or another modality.

Selected patients with pseudomyxoma peritonei, appendix cancer, peritoneal mesothelioma, ovarian cancer and certain colorectal or stomach cancers may be considered. Evidence differs by disease — see HIPEC surgery in India.

No. Stage 4 can mean different patterns of spread. HIPEC is mainly considered when disease involves the peritoneum and surgery may remove visible deposits.

Some carefully selected patients may achieve long-term control and, in certain situations, a possible chance of cure. HIPEC is not a guaranteed cure and recurrence is possible.

Yes. Neoadjuvant systemic chemotherapy may shrink disease, treat micrometastases and help decide whether surgery is useful.

Not for everyone. Further systemic therapy depends on pathology, prior treatment, operative findings and recovery.

They differ. Systemic chemotherapy can cause whole-body effects such as fatigue, nausea and low blood counts. CRS-HIPEC adds major surgical risks to chemotherapy-related effects.

Yes. CRS-HIPEC usually involves a major abdominal operation that may remove deposits and sometimes organs or bowel segments.

Often many hours, depending on disease extent and reconstructions. GAF CRS-HIPEC planning typically quotes 10–21 nights in hospital.

Hospital stay varies; full recovery often takes several weeks or longer. Systemic chemotherapy recovery is measured in days between cycles rather than weeks after major surgery.

Standard HIPEC is usually delivered during cytoreductive surgery. Other intraperitoneal approaches such as catheter IP chemotherapy or PIPAC are different pathways.

It may be discussed for selected colorectal peritoneal metastases. ASCO does not recommend adding oxaliplatin-based HIPEC to CRS for colorectal peritoneal metastases; CRS plus systemic chemotherapy may still be considered when complete cytoreduction is feasible.

It may be considered for selected women with stage III epithelial ovarian cancer during interval cytoreductive surgery after chemotherapy. It is not suitable for every ovarian cancer patient — see ovarian cancer treatment in India.

Not routinely for every patient with peritoneal spread. Systemic treatment remains central; CRS-HIPEC is considered only in selected specialist settings — see HIPEC surgery for stomach cancer.

CT or MRI, pathology review, blood and organ-function tests, tumour markers where relevant, and sometimes diagnostic laparoscopy.

The Peritoneal Cancer Index describes disease burden across 13 abdominal regions (0–39). It helps planning but is not a universal pass/fail rule — see the PCI guide.

Yes, at selected specialist centres with peritoneal oncology experience, ICU support and HIPEC equipment. Confirm centre experience for the specific cancer.

GAF planning for CRS with HIPEC is $18,000–$40,000 (10–21 nights). Systemic chemotherapy planning is $1,500–$8,000+ for typical outpatient cycles. Final quotations follow case review.

Often yes. Share pathology, DICOM imaging, prior treatment details and recent blood tests for an initial review. Final eligibility may still need in-person assessment.

No. Do not stop or change prescribed chemotherapy without the treating oncologist. Timing of systemic therapy and any surgery must be coordinated.

Repeat CRS-HIPEC is considered only in a small number of carefully selected cases, depending on recurrence pattern, prior surgery and fitness.

A multidisciplinary team must review pathology, scans, prior therapy and fitness. They can explain whether systemic chemotherapy, surgery, HIPEC or a combination fits the case.

Understanding whether peritoneal disease needs systemic chemotherapy, cytoreductive surgery, HIPEC or a combination starts with pathology and imaging review.

GAF Healthcare assists international patients exploring cancer treatment in India by coordinating medical records, specialist consultations and treatment-related arrangements. Website: https://gaf.healthcare/.

This article is for educational purposes only and does not replace medical consultation, diagnosis or individualised advice. CRS-HIPEC is a complex operation with significant risks. Suitability must be determined by a qualified multidisciplinary team. Cost figures are indicative planning ranges. Emergency symptoms belong in a local emergency department.